Thermo Fisher Scientific is trading 3.12% up in pre-market at $622.01 after UBS upgraded the shares to Buy from Neutral and raised its price target from $540 to $730.
- UBS expects 5%–6% organic revenue growth by 2027, expanding operating margins, and double-digit earnings-per-share growth.
- Major index futures are up roughly 0.5%, supporting the positive pre-market tone.